Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IMTXW 
immatics biotechnologies GmbH (IMTXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: IMTXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -51.05% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 673.00M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 16474 | Beta 0.83 | 52 Weeks Range 0.02 - 4.00 | Updated Date 03/29/2025 |
52 Weeks Range 0.02 - 4.00 | Updated Date 03/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 9.77% | Operating Margin (TTM) 1.61% |
Management Effectiveness
Return on Assets (TTM) -4% | Return on Equity (TTM) 3.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 66121139 |
Shares Outstanding - | Shares Floating 66121139 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
immatics biotechnologies GmbH
Company Overview
History and Background
immatics biotechnologies GmbH was founded in 2000. It's a clinical-stage biopharmaceutical company focusing on the discovery and development of T cell receptor (TCR)-based immunotherapies for cancer. Key milestones include developing its XPRESIDENT and ACTengine platforms.
Core Business Areas
- Adoptive Cell Therapies (ACT): Development of personalized cell therapies using the patient's own T cells engineered to target specific cancer antigens.
- Antibody-like TCR Bispecifics: Creation of TCR-based bispecific molecules designed to redirect T cells to tumor cells.
- Target Discovery: Identification of novel cancer targets to enable the development of immunotherapies.
Leadership and Structure
The leadership team includes Carsten Reinhardt (CEO). The organizational structure is based on functional departments such as R&D, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- IMA203: A TCR-engineered cell therapy targeting PRAME. Currently in clinical development. Competitors include companies developing similar TCR-T therapies, such as Adaptimmune Therapeutics (ADAP). Market share data not publicly available.
- IMA401: A TCR-bispecific molecule targeting MAGEA4/8. Currently in clinical development. Competitors are companies developing bispecifics in oncology, such as Amgen (AMGN) and Regeneron (REGN). Market share data not publicly available.
Market Dynamics
Industry Overview
The oncology immunotherapy market is rapidly growing, driven by advancements in cell and gene therapies. There's intense competition, with numerous companies developing novel approaches to treat cancer.
Positioning
immatics is positioned as a leader in TCR-based immunotherapies, with a focus on developing innovative therapies for solid tumors.
Total Addressable Market (TAM)
The TAM for cancer immunotherapies is estimated to be over $100 billion. immatics is targeting a portion of this market with its TCR-based therapies.
Upturn SWOT Analysis
Strengths
- Proprietary TCR discovery and engineering platforms (XPRESIDENT and ACTengine)
- Strong intellectual property portfolio
- Experienced management team
- Focus on difficult-to-treat solid tumors
Weaknesses
- Clinical development is inherently risky
- Reliance on partnerships for funding
- Manufacturing complexities associated with cell therapies
- High competition in the immunotherapy space
Opportunities
- Expansion of pipeline with new TCR-based therapies
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new cancer indications
Threats
- Clinical trial failures
- Competition from other immunotherapy companies
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- ADAP
- TCR2
- ZIOP
Competitive Landscape
immatics advantages includes its TCR-engineering platforms. Disadvantages may include clinical trial risk and competition.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth trends can be determined by analyzing historical financial reports of IMTX.
Future Projections: Future growth projections are based on analyst estimates and are based on IMTX pipeline success and partnerships.
Recent Initiatives: Recent initiatives include advancing its clinical pipeline and forging strategic partnerships.
Summary
Immatics is a clinical-stage company pioneering TCR-based immunotherapies, facing strong competition in the immunotherapy market. Its strengths lie in its proprietary platforms, while risks involve clinical trial outcomes and manufacturing complexities. Future success depends on pipeline advancement, partnerships, and competitive differentiation. Immatics is currently positioned to capture a percentage of TAM but requires future catalysts.
Similar Companies
- ADAP
- TCR2
- ZIOP
- BMY
- PFE
- MRK
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and may vary. Investment decisions should be based on thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About immatics biotechnologies GmbH
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-07-02 | CEO, MD, Member of Management Board & Executive Director Dr. Harpreet Singh Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.immatics.com |
Full time employees - | Website https://www.immatics.com | ||
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.